FIELD: chemistry.
SUBSTANCE: invention relates to a compound with formula (Ib) or a pharmaceutically acceptable salt, solvate or tautomer thereof, wherein X1 is O; R 1 is chosen from the group consisting of ring structures (a), where 
is a single bond; each A is independently CR5a or N; each A 2 is independently C(R5a ) 2, NR 5a or O and at least one A 2 is NR 5a or O; R 2 is a structure chosen from (b), X2 is N or CR5b ; R3 and R4 are H; each R5a is independently H, halogen, -OH, -CN, SR 6, -OR6, -NHR6, -NR6 R7, C1-C6 alkyl, C2 -C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, monocyclic heterocyclyl or -CH2 -C3 -C8 cycloalkyl; where C1-C 6 alkyl, C2 -C6 alkenyl, C2 -C6 alkynyl, C3-C8 cycloalkyl, monocyclic heterocyclyl and -CH2-C 3 -C 8 cycloalkyl are optionally substituted with halogen, C1 -C6 alkyl, -OR6, -NH2, NH(C1 -C6 alkyl) or N(C -C6 alkyl)2 ; or two R5a together with the atoms to which they are attached may form a C3 -C8 cycloalkyl or monocyclic heterocyclyl; wherein the monocyclic heterocyclyl contains 1-3 heteroatoms chosen from the group consisting of N, S, P and O; where C3 -C8 cycloalkyl or monocyclic heterocyclyl is optionally substituted with halogen, C1 -C6 alkyl, -OR6, -NH2, NH(C1-C6 alkyl) or N(C1-C6 alkyl) 2 ; or two geminal R 5a may form an oxo group; each R5b is independently H, halogen, -OH, -CN, -SR6, -OR6, NHR6, -NR6 R7, or C1-C 6 alkyl; where C1 -C 6 alkyl is optionally substituted with halogen, -OR 6, -NH 2, -NH(C1-C6 alkyl) or -N(C1-C 6 alkyl)2; R6 and R7 are independently at each occurrence H, C1-C 8 alkyl, C 2 -C 8 alkenyl, or C2-C 8 alkynyl; where C1-C6 alkyl, C2-C 8 alkenyl and C2-C 6 alkynyl are optionally substituted with halogen, C1-C6 alkyl, -OH, -OC1-C6 alkyl, -NH2, -NH(C1-C6 alkyl) or -N(C1-C 6 alkyl)2; or R6 and R7 together with the atom to which they are attached may form a monocyclic heterocyclyl containing 1-3 heteroatoms chosen from the group consisting of N, S, P and O; and n is an integer from 0 to 5. The invention also relates to specific sulfonylurea compounds listed in the claims. The invention relates to a pharmaceutical composition for inhibiting the activation of the NLRP3 inflammasome, containing a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, solvate or tautomer thereof, and a pharmaceutically acceptable carrier.
EFFECT: sulfonylurea derivatives inhibiting the activation of the NLRP3 inflammasome.
44 cl, 6 dwg, 5 tbl, 89 ex
or 
| Title | Year | Author | Number |
|---|---|---|---|
| SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | 2019 |
|
RU2820289C2 |
| INHIBITION OF CREB-BINDING PROTEIN (CBP) | 2019 |
|
RU2803290C2 |
| COMPOUNDS 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE | 2017 |
|
RU2719599C2 |
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
| PYRAZOLINE DIONE DERIVATIVES AS NADPH-OXIDASE INHIBITORS | 2010 |
|
RU2569855C2 |
| SULFONYL UREA AND RELATED COMPOUNDS AND USE THEREOF | 2016 |
|
RU2739356C2 |
| NOVEL PYRAZOLE DERIVATIVES | 2022 |
|
RU2816835C1 |
| GETEROCYCLILPYRIDINYLPYRAZOLS AS FUNGICIDAL AGENTS | 2012 |
|
RU2616293C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2019 |
|
RU2795108C2 |
